Literature DB >> 19058986

Pathological abnormalities after long-term administration of medroxyprogesterone acetate in a queen.

Abdulkadir Keskin1, Gulnaz Yilmazbas, Rahsan Yilmaz, Musa O Ozyigit, Ahmet Gumen.   

Abstract

In this report, multiple abnormalities (bilateral ovarian cysts, cystic endometrial hyperplasia and pyometra (CEH-P), mammary adenoma, fibrosarcoma and cystic-papillary adenocarcinoma) identified in a queen continually administered medroxyprogesterone acetate (MPA) for 9 years are described. An 11-year-old domestic shorthair intact queen was presented for reduced appetite, polyuria, polydipsia, abdominal distension, and mammary mass. Pyometra was diagnosed based upon clinical, ultrasonographic and radiographic examinations. Mastectomy and ovariohysterectomy (OHE) were performed for treatment. Bilateral ovarian cysts were detected during OHE. Histopathologically, follicular ovarian cysts, CEH-P, and benign and neoplastic mammary lesions were identified. We suggest that, the pathological abnormalities may have been attributed to adverse effects of prolonged administration of MPA.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19058986     DOI: 10.1016/j.jfms.2008.10.006

Source DB:  PubMed          Journal:  J Feline Med Surg        ISSN: 1098-612X            Impact factor:   2.015


  3 in total

1.  Strain specific induction of pyometra and differences in immune responsiveness in mice exposed to 17α-ethinyl estradiol or the endocrine disrupting chemical bisphenol A.

Authors:  Jessica A Kendziorski; Eric L Kendig; Robin B Gear; Scott M Belcher
Journal:  Reprod Toxicol       Date:  2012-03-10       Impact factor: 3.143

2.  Semi-Ownership and Sterilisation of Cats and Dogs in Thailand.

Authors:  Samia R Toukhsati; Clive J C Phillips; Anthony L Podberscek; Grahame J Coleman
Journal:  Animals (Basel)       Date:  2012-11-06       Impact factor: 2.752

Review 3.  Feline breeding and pregnancy management: What is normal and when to intervene.

Authors:  Bodil Ström Holst
Journal:  J Feline Med Surg       Date:  2022-03       Impact factor: 1.971

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.